secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001193805-24-000842
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Therapeutics appoints Dr. Moncef Slaoui to Board of Directors
----------------------------------------------------------------------

- Dr. Moncef Slaoui, former Chief Scientific Advisor for Operation Warp Speed, appointed independent director effective June 19, 2024.
- Slaoui brings vaccine industry expertise; previously served on boards of Moderna, Lonza, Vaxcyte, and held leadership at GSK.
- Slaoui will receive standard non-employee director compensation as described in 2024 proxy statement.
- No arrangements or family relationships with other directors/officers; no reportable transactions under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000842/0001193805-24-000842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000842/e663734_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer